We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-11.71%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
-$80.6M
Cap. Flow
+$72.2M
Cap. Flow %
6.86%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$72.5M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$308K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$277M
$715M 67.97%
9,699,925
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.28B
$116M 11%
3,504,624
– –
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$70.9M 6.74%
2,444,311
– –
PHVS icon
4
Pharvaris
PHVS
$2.48B
$64.4M 6.12%
+2,303,310
New +$72.5M
CMPI
5
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$44.6M 4.24%
3,673,374
– –
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$21M 2%
490,471
– –
MTCR
7
DELISTED
Metacrine, Inc. Common Stock
MTCR
$19M 1.8%
3,059,123
– –
VRNA
8
DELISTED
Verona Pharma
VRNA
$1.35M 0.13%
161,897
-37,178
-19% -$308K

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q1 2021 Portfolio in Review

As of Q1 2021, venBio Partners held 8 positions worth $1.05B, down 7.1% from $1.13B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $72.2M of net new capital in Q1 2021, opening 1 new position. Its largest new stake was Pharvaris: 2,303,310 shares worth $64.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $308K trimmed.

  • venBio Partners's largest Q1 2021 buy was Pharvaris: 2,303,310 shares worth $64.4M.
  • venBio Partners's biggest Q1 2021 reduction was Verona Pharma, cutting an estimated $308K.
  • venBio Partners's ten largest holdings make up 100% of its $1.05B portfolio in Q1 2021.
  • venBio Partners opened 1 new position and closed 0 in Q1 2021.
  • venBio Partners's portfolio value fell 7.1% quarter-over-quarter to $1.05B.

Based on venBio Partners's 13F filing for Q1 2021, filed 17 May 2021.